This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (42) Citing Articles via Google Scholar Google Scholar Articles by Knutson, J. E. Articles by Mullany, C. J. Search for Related Content PubMed PubMed Citation Articles by Knutson, J. E. Articles by Mullany, C. J.

---

CARDIOVASCULAR ANESTHESIA

Does Intraoperative Hetastarch Administration Increase Blood Loss and Transfusion Requirements After Cardiac Surgery?

Jill E. Knutson, BSN, SRNA^*, Jane A. Deering, SRNA, PhD^*, Frank W. Hall, BSN, SRNA^*, Gregory A. Nuttall, MD, Darrell R. Schroeder, MS, Roger D. White, MD, and Charles J. Mullany, MD^§

*Mayo School of Health-Related Sciences; Department of Anesthesiology, Mayo Graduate School of Medicine; Department of Health Sciences Research, Mayo Clinic; §Department of Cardiac Surgery, Mayo Graduate School of Medicine, Rochester, Minnesota

Address correspondence and reprint requests to Gregory A. Nuttall, MD, Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905. Address e-mail to nuttall.gregory{at}mayo.edu

Hetastarch is used for intravascular volume expansion in cardiac surgery. Studies show conflicting effects of intraoperative hetastarch administration on postoperative bleeding. Hetastarch was routinely used for volume expansion during cardiovascular surgeries at our institution until its use was discontinued intraoperatively. We performed a retrospective chart review on patients undergoing primary coronary artery bypass grafting, valve repair or replacement requiring cardiopulmonary bypass (n = 444), 234 of which received intraoperative hetastarch and 210 did not. There was no difference in demographics, cardiac surgery, or cardiopulmonary bypass duration between the two groups. Blood loss for 0–4 h postoperatively was 377 ± 244 mL in the group not receiving hetastarch compared with 515 ± 336 mL in the group that received hetastarch (P < 0.001). For 0–24 h postoperatively, blood loss was 923 ± 473 mL versus 1,283 ± 686 mL in the absence and presence of hetastarch, respectively (P < 0.001). Allogeneic transfusion requirements (cryoprecipitate, fresh frozen plasma, and platelets) were larger in the hetastarch group (all P < 0.001). Nearly all (99%) patients in the hetastarch group received less than the manufacturer’s recommended dose (20 mL/kg) of hetastarch.

Implications: Our large retrospective study suggests that intraoperative use of hetastarch in primary cardiac surgery with cardiopulmonary bypass may increase bleeding and transfusion requirements. A large prospective study is needed to determine if intraoperative administration of hetastarch should be avoided during cardiovascular surgery.

This article has been cited by other articles:

				J. Boldt, S. Suttner, C. Brosch, A. Lehmann, K. Rohm, and A. Mengistu Cardiopulmonary Bypass Priming Using a High Dose of a Balanced Hydroxyethyl Starch Versus an Albumin-Based Priming Strategy Anesth. Analg., December 1, 2009; 109(6): 1752 - 1762. [Abstract] [Full Text] [PDF]

				M. Hecht-Dolnik, H. Barkan, A. Taharka, and J. Loftus Hetastarch increases the risk of bleeding complications in patients after off-pump coronary bypass surgery: A randomized clinical trial J. Thorac. Cardiovasc. Surg., September 1, 2009; 138(3): 703 - 711. [Abstract] [Full Text] [PDF]

				J. Ooi Su Min, A. R. M. Ramzisham, and M. D. Zamrin Is 6% Hydroxyethyl Starch 130/0.4 Safe in Coronary Artery Bypass Graft Surgery? Asian Cardiovasc Thorac Ann, August 1, 2009; 17(4): 368 - 372. [Abstract] [Full Text] [PDF]

				The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]

				J. Boldt, M. Wolf, and A. Mengistu A New Plasma-Adapted Hydroxyethylstarch Preparation: In Vitro Coagulation Studies Using Thrombelastography and Whole Blood Aggregometry Anesth. Analg., February 1, 2007; 104(2): 425 - 430. [Abstract] [Full Text] [PDF]

				R. Arellano, B. S. Gan, M. J. Salpeter, E. Yeo, S. McCluskey, R. Pinto, J. Irish, D. C. Ross, D. J. Doyle, J. Parkin, et al. A Triple-Blinded Randomized Trial Comparing the Hemostatic Effects of Large-Dose 10% Hydroxyethyl Starch 264/0.45 Versus 5% Albumin During Major Reconstructive Surgery Anesth. Analg., June 1, 2005; 100(6): 1846 - 1853. [Abstract] [Full Text] [PDF]

				M. P. W. Grocott, M. G. Mythen, and T. J. Gan Perioperative Fluid Management and Clinical Outcomes in Adults Anesth. Analg., April 1, 2005; 100(4): 1093 - 1106. [Abstract] [Full Text] [PDF]

				Evidence-based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement Am. J. Respir. Crit. Care Med., December 1, 2004; 170(11): 1247 - 1259. [Full Text] [PDF]

				M. M. Wilkes, R. J. Navickis, J. Avorn, and W. Winkelmayer Hydroxyethyl Starch-Induced Postoperative Bleeding in Cardiac Surgery Patients: More Trials Needed? Chest, July 1, 2004; 126(1): 311 - 312. [Full Text] [PDF]

				A. Shander, T. Rijhwani, D. Moskowitz, and R. Spence Blood and Starch in Cardiac Surgery Chest, June 1, 2004; 125(6): 2369 - 2370. [Full Text] [PDF]

				M. E. Barron, M. M. Wilkes, and R. J. Navickis A Systematic Review of the Comparative Safety of Colloids Arch Surg, May 1, 2004; 139(5): 552 - 563. [Abstract] [Full Text] [PDF]

				J. Boldt New Light on Intravascular Volume Replacement Regimens: What Did We Learn from the Past Three Years? Anesth. Analg., December 1, 2003; 97(6): 1595 - 1604. [Abstract] [Full Text] [PDF]

				J. Avorn, M. Patel, R. Levin, and W. C. Winkelmayer Hetastarch and Bleeding Complications After Coronary Artery Surgery Chest, October 1, 2003; 124(4): 1437 - 1442. [Abstract] [Full Text] [PDF]

				A. Sedrakyan, K. Gondek, D. Paltiel, and J. A. Elefteriades Volume Expansion With Albumin Decreases Mortality After Coronary Artery Bypass Graft Surgery Chest, June 1, 2003; 123(6): 1853 - 1857. [Abstract] [Full Text] [PDF]

				T. Standl, M.-A. Burmeister, F. Schroeder, E. Currlin, J. Schulte am Esch, M. Freitag, and J. Schulte am Esch Hydroxyethyl Starch (HES) 130/0.4 Provides Larger and Faster Increases in Tissue Oxygen Tension in Comparison with Prehemodilution Values than HES 70/0.5 or HES 200/0.5 in Volunteers Undergoing Acute Normovolemic Hemodilution Anesth. Analg., April 1, 2003; 96(4): 936 - 943. [Abstract] [Full Text] [PDF]

				M. C. Engoren, R. H. Habib, A. Zacharias, T. A. Schwann, C. J. Riordan, and S. J. Durham Effect of blood transfusion on long-term survival after cardiac operation Ann. Thorac. Surg., October 1, 2002; 74(4): 1180 - 1186. [Abstract] [Full Text] [PDF]

				M. M. Wilkes, R. J. Navickis, and W. J. Sibbald Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding Ann. Thorac. Surg., August 1, 2001; 72(2): 527 - 533. [Abstract] [Full Text] [PDF]

				E. Huettemann and G. A. Nuttall Hetastarch and Hydroxyethyl Starch Are Not the Same Response Anesth. Analg., December 1, 2000; 91(6): 1561 - 1561. [Full Text] [PDF]